CMPS News and Press, COMPASS Pathways Plc From 01/05/24

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Greenbrook TMS Inc. (NASDAQ: GBNH) (“Greenbrook TMS”), a ...

Last week, President Joe Biden signed a defense bill containing provisions to finance trials into the therapeutic potential for psychedelics for military services members in active duty. This came a week after Congress gave its final approval and forwarded the bill to the president’s des...

Research in the psychedelic field has flourished in 2023, with the latest studies showing that psilocybin may be legalized in a couple of years. Below, we look at key clinical studies that suggest optimal psilocybin dosing for mental health conditions such as depression. COMP360 Psilocybin ther...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that an initial data readout showed that investigational COMP360...

Last week, the Drug Enforcement Administration (DEA) suggested that DOC and DOI be classified under Schedule I of the Controlled Substances Act in its latest notice. DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) are both psychedelic drugs of the amphetamine...

The campaign behind a ballot measure in California to legalize psychedelic substances has presented a final amended resolution to officials in the state. Various changes have been made to the initiative following a public comment period that concluded in November. For instance, the changes ex...

A recent review of scientific psychedelic research has suggested that hallucinogens such as psilocybin (magic mushrooms) and LSD may be more effective at managing pain compared to opioids. The review indicates that classic psychedelics may be effective at mitigating the physical agony caused b...

2023-12-07 07:21:16 ET More on COMPASS Pathways: Compass Pathways: Private Placement Buys Less Time Than Expected COMPASS Pathways GAAP EPS of -$0.67 misses by $0.21 Psychedelics research amendments advance in House committee Seeking Alpha’s Quant Rati...

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO...

LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in JAMA Psychiatry that dem...